Selective KRAS dependency in cancer: Therapeutic implications for KRAS-mutant tumors

KRAS is a well-established oncogene and a key driver of various cancers, particularly pancreatic, colorectal, and lung cancers. This study explored the selective dependency of cancer cells on KRAS, highlighting its potential as a therapeutic target. DepMap analysis revealed that KRAS dependency was highly tumor-type specific, with significant reliance observed in cancer cell lines harboring KRAS mutations. Both CRISPR knockout and RNAi screens consistently demonstrated that KRAS-mutant cancer cells were critically dependent on KRAS for survival. In pancreatic cancer cell lines, KRAS knockout resulted in a pronounced reduction in cell viability, underscoring its role as a vital driver of cancer cell proliferation. Immunohistochemical analysis further revealed variable KRAS protein expression across cancer types, suggesting context-dependent KRAS dysregulation in tumorigenesis. These findings highlight KRAS as a critical and selective vulnerability in pancreatic and other KRAS-driven cancers, emphasizing the need for personalized therapeutic strategies. As KRAS inhibitors continue to advance in clinical development, they hold promise for significantly improving outcomes in patients with KRAS-driven malignancies.